Mer (IC50 = 0.74 nM); FLT3 (IC50 = 0.8 nM); Axl (IC50 = 14 nM); Tyro3 (IC50 = 17 nM)

UNC2025 has IC50 values of 0.35 nM, 0.46 nM, 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM, and 364 nM against FLT3, MER, AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, KIT, and Met, respectively[1].
UNC2025 (0-60 nM; 1 hour) effectively inhibits Mer phosphorylation at an IC50 of 2.7 nM in 697 B-ALL cells[1].
UNC2025 (0-60 nM; 1 hour) results in Flt3-ITD positive Molm-14 acute myeloid leukemia cells having reduced Flt3 phosphorylation with an IC50 of 14 nM[1].
UNC2025 (3 nM-3 μM; 1 hour) reduces the expression of p-MEK, p-AXL, and p-TYRO3 in 32D cells in a concentration-dependent manner[1].
UNC2025 (14 nM–10 μM; 48 hours) suppresses MERTK signaling and colony-forming ability in a patient sample that expresses MERTK, with MERTK-expressing leukemia blasts exhibiting a 20-fold increase in sensitivity compared to normal cord or marrow blood mononuclear cells[2].
UNC2025 (25-300 nM; 1 hour) inhibits MERTK, which in turn correlates with a decrease in the phosphorylation of previously identified MERTK-dependent signaling components, including STAT6, AKT, and ERK1/2. Mediates strong and dose-dependent decreases in MERTK phosphorylation/activation in both cell lines[2].

UNC2025 (intravenous injection or oral adminstration; 3 mg/kg) demonstrates exceptional pharmacokinetic characteristics, including low clearance (9.2 mL/min kg), extended half-life (3.8 h), and 100% oral exposure. Its T_max, C_max, and AUClast values are 0.50 hour, 1.6 μM, and 9.2 h μM, respectively[2].
UNC2025 (orally adminstration; 50 or 75 mg/kg; 34 and 70 days) mediates a dose-dependent tumor burden reduction that is statistically significant when compared to the vehicle. facilitates dose-dependent increases in the median survival in mice receiving vehicle treatment, which is 26 days after treatment initiation, to 34 and 70 days in mice receiving 50 or 75 mg/kg UNC2025, respectively[2].

---

UNC2025 is a potent and highly oral bioavailable Mer inhibitor that, by pharmacodynamic (PD) studies looking at phospho-Mer in leukemic blasts from mouse bone marrow, is able to inhibit Mer phosphorylation in vivo after oral dosing.[1]

---

UNC2025 had significant therapeutic effects in xenograft models, with dose-dependent decreases in tumor burden and consistent two-fold increases in median survival, irrespective of starting disease burden. In a patient-derived AML xenograft model, treatment with UNC2025 induced disease regression. In addition, UNC2025 increased sensitivity to methotrexate in vivo, suggesting that addition of MERTK-targeted therapy to current cytotoxic regimens may be particularly effective and/or allow for chemotherapy dose reduction.Conclusions: The broad-spectrum activity mediated by UNC2025 in leukemia patient samples and xenograft models, alone or in combination with cytotoxic chemotherapy, supports continued development of MERTK inhibitors for treatment of leukemia. [2]

Kinome Profiling Using ActivX ATP/ADP Probes[1]
Briefly, 697 B-ALL cells were gently pelleted, washed twice with PBS, lysed using MPER supplemented with HALT protease/phosphatase inhibitor cocktail, and subjected to Zeba gel filtration spin columns to remove residual ATP and ADP. Following filtration, the final protein concentration was adjusted to 5.0 mg/mL using reaction buffer and supplemented with additional 1X HALT protease and phosphatase inhibitor cocktail. Lysate was aliquoted, snap frozen in liquid nitrogen, and stored at −80 °C until labeling. Prior to labeling, 2.5 mg of total lysate (final volume, 500 μL) was thawed to room temperature and treated with 10 μL of 1 M MnCl2 for 1 min. Then the lysate was treated with or without UNC2025 [0, 0.01, 0.1, 1.0, 10, 100, and 1000 nM] for 10 min. Following treatment, the ATP probe was added for 10 min at a final concentration of 5 μM. The labeling reaction was quenched with 500 μL of 10 M urea in MPER, 10 μL of 500 mM DTT, and heated to 65 °C for 30 min with shaking. Samples were cooled to room temperature and alkylated with 40 μL of a 1 M iodoacetamide solution for 30 min protected from light. The solution was then subjected to Zeba gel filtration and digested with 20 μg of trypsin at 37 °C for 2 h with shaking. 50 μL of a 50% high capacity streptavidin agarose slurry was added and allowed to incubate for 1 h at room temperature with constant mixing on a rotator. Agarose beads were then captured, washed, and eluted. Purified peptides were frozen, lyophilized, and stored at −80 °C. Immediately before mass spectrometric analysis, peptides were resuspended in 25 μL of 0.1% TFA. Details on mass spectrometry analysis and data analysis are provided in the Supporting Information.

---

Cell-Based Assays for Kinase Inhibition[1]
697 B-ALL cells and Molm-14 AML cells were cultured in the presence of UNC2025 or vehicle-only for 1.0 h. Pervanadate solution was prepared fresh by combining 20 mM sodium orthovanadate in 0.9× PBS in a 1:1 ratio with 0.3% (w/w) hydrogen peroxide in PBS for 15–20 min at room temperature. Cultures were treated with 120 μM pervanadate for 3 min prior to collection, and cell lysates were prepared in 50 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM EDTA, 10% glycerol, and 1% Triton X-100, supplemented with protease inhibitors. Mer and Flt3 proteins were immunoprecipitated with anti-Mer or anti-Flt3 antibody and Protein G agarose beads. Phospho-proteins were detected by Western blot using an antiphospho-Mer antibody raised against a peptide derived from the triphosphorylated activation loop of Mer8 or an antibody specific for phosphorylated Flt3. Nitrocellulose membranes were stripped and total proteins were detected using a second anti-Mer antibody or anti-Flt3 antibody. Relative phosphorylated and total protein levels were determined by densitometry using ImageJ, and IC50 values were calculated by nonlinear regression.

---

UNC2025 hydrochloride has an IC50 of 0.8/0.74 nM for Mer/Flt3, making it a strong and orally bioavailable dual inhibitor of Mer/Flt3. Studies using pharmacodynamic (PD) methods to look at phospho-Mer in leukemic blasts from mouse bone marrow showed that UNC2025 could inhibit Mer phosphorylation in vivo after oral dosing. The results of kinome profiling against over 300 kinases in vitro and cellular selectivity assessments show that UNC2025 has pharmacologically useful selectivity compared to other kinases examined and has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML).

Soft Agar Colony Formation Assays[1]
A549 or Molm-14 cells were cultured in 1.5 mL of 0.35% soft agar containing 1× RPMI medium and 10% FBS and overlaid with 2.0 mL of 1× RPMI medium containing 10% FBS and the indicated concentrations of UNC2025 or DMSO vehicle only. Medium and UNC2025 or vehicle were refreshed 3 times per week. Colonies were stained with nitrotetrazolium blue chloride and counted after 2 weeks.

---

Immunoblot analysis[1]
Leukemia cells (3x106/mL) were cultured with UNC2025 or DMSO equivalent to 300nM UNC2025 for one hour. Cell lysates were prepared and signaling proteins were detected by immunoblot. Cells were treated with pervanadate and MERTK was immunoprecipitated to detect phosphorylated MERTK.

---

Apoptosis, cell cycle, and colony formation assays[1]
Cells were cultured (3x10~5/mL) for 6, 24, and/or 48 hours with UNC2025 or DMSO. Apoptotic and dead cells were detected by flow cytometry after staining with YO-PRO-1-iodide and propidium-iodide, cell cycle profiles were determined by assessment of propidium iodide staining in permeabilized cells using flow cytometry, and MTT reduction was determined as an indicator of viable cell number. Alternatively, ALL cell lines and patient samples were cultured in methylcellulose after treatment. AML cell lines were cultured in 0.35% Noble agar overlaid with medium containing UNC2025 or vehicle. Human mononuclear cells from normal bone marrow or umbilical cord blood were cultured in methylcellulose containing UNC2025 or DMSO. Colonies were counted after 7 (normal marrow) or 14 (umbilical cord blood, cell lines and patient samples) days.

---

UNC-2025 has a 2.7 nM IC50 and can potently inhibit Mer phosphorylation in 697 B-ALL cells. UNC-2025, which is reliant on Flt3 and Mer8, significantly inhibits colony formation in A549 NSCLC and Molm-14 AML cell lines. UNC2025 blocks MERTK oncogenic signaling downstream in H2228 and H1299 cell lines, including basal and stimulated pAKT and pERK1/2. Additionally, UNC-2025 inhibits colony formation and triggers apoptotic cell death in four NSCLC cell lines.

NSG mice injected with 697 B-ALL cells[2]
50 or 75 mg/kg
Oral adminstration

---

Pharmacodynamic Studies[1]
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were transplanted with 2 × 106 697 B-ALL cells by intravenous injection into the tail vein, and leukemia was established for 14 days prior to treatment with a single dose of 3 mg/kg 11 (UNC2025) or an equivalent volume (10 mL/kg) of saline vehicle. Pervanadate solution was prepared fresh, as described above. Femurs were collected from mice 30 min after treatment, and bone marrow cells were flushed with 1 mL of room temperature RPMI medium + 20% FBS + 1 μM MgCl2 + 100 untis/ml DNase + 240 μM pervanadate and incubated at room temperature in the dark for 10 min. Bone marrow cells were collected by centrifugation at 4 °C, lysates were prepared, Mer protein was immunoprecipitated, and total and phospho-Mer proteins were detected and quantitated by Western blot, as described above.

---

Leukemia xenograft models[2]
697 cells, monoclonal 697 cells expressing firefly luciferase (20), NOMO-1 cells, or mononuclear cells from an AML patient sample (2x106/mouse) were injected into the tail vein in NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) or NOD.Cg-PrkdcscidIl2rgtm1WjlTg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (NSGS) mice. Disease burden was monitored in 697-luciferase xenografts using bioluminescence imaging. Peripheral blood, spleen, and bone marrow were collected from patient-derived xenografts and red blood cells (RBCs) were lysed in 50% Dextran sulfate for 15 minutes. Human CD45+ cells were detected using flow cytometry. Mice were distributed to groups with statistically equal disease burden or randomized to groups if leukemia was undetectable. UNC2025 or saline was administered at 10ml/kg once daily by oral gavage. Methotrexate or saline was administered at 5ml/kg by intraperitoneal injection. Mice with advanced leukemia (>20% weight loss, tachypnea, hypothermia, hind-limb paralysis, minimal activity) were euthanized and survival was monitored. Pharmacodynamic studies were performed as previously described

[1]. UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. J Med Chem. 2014 Aug 28;57(16):7031-41.

[2]. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with CL14377 in Leukemia Models.Clin Cancer Res. 2017 Mar 15;23(6):1481-1492.

We previously reported a potent small molecule Mer tyrosine kinase inhibitor UNC1062. However, its poor PK properties prevented further assessment in vivo. We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow. Kinome profiling versus more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an additional important target in acute myelogenous leukemia (AML), with pharmacologically useful selectivity versus other kinases examined.[1]

---

Purpose: MERTK tyrosine kinase is ectopically expressed in 30% to 50% of acute lymphoblastic leukemias (ALL) and more than 80% of acute myeloid leukemias (AML) and is a potential therapeutic target. Here, we evaluated the utility of UNC2025, a MERTK tyrosine kinase inhibitor, for treatment of acute leukemia.Experimental Design: Preclinical in vitro and in vivo assays using cell lines and primary leukemia patient samples were used to evaluate antileukemic effects of UNC2025.Results: UNC2025 potently inhibited prosurvival signaling, induced apoptosis, and reduced proliferation and colony formation in MERTK-expressing ALL and AML cell lines and patient samples. Approximately 30% of primary leukemia patient samples (78 of 261 total) were sensitive to UNC2025. Sensitive samples were most prevalent in the AML, T-ALL, and minimally differentiated (M0) AML subsets. UNC2025 inhibited MERTK in bone marrow leukemia cells and had significant therapeutic effects in xenograft models, with dose-dependent decreases in tumor burden and consistent two-fold increases in median survival, irrespective of starting disease burden. In a patient-derived AML xenograft model, treatment with UNC2025 induced disease regression. In addition, UNC2025 increased sensitivity to methotrexate in vivo, suggesting that addition of MERTK-targeted therapy to current cytotoxic regimens may be particularly effective and/or allow for chemotherapy dose reduction.Conclusions: The broad-spectrum activity mediated by UNC2025 in leukemia patient samples and xenograft models, alone or in combination with cytotoxic chemotherapy, supports continued development of MERTK inhibitors for treatment of leukemia.[2]

C28H41CLN6O

513.1177

512.303

2070015-17-5

UNC2025;1429881-91-3

92044362

Light yellow to yellow solid

3

6

8

36

627

0

NYHAEAZNSGIAPV-UHFFFAOYSA-N

InChI=1S/C28H40N6O.ClH/c1-3-4-13-29-28-30-18-25-26(20-34(27(25)31-28)23-9-11-24(35)12-10-23)22-7-5-21(6-8-22)19-33-16-14-32(2)15-17-33;/h5-8,18,20,23-24,35H,3-4,9-17,19H2,1-2H3,(H,29,30,31);1H

4-[2-(butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol;hydrochloride

UNC-2025 HCl; UNC-2025 hydrochloride; UNC2025 hydrochloride; UNC 2025 HCl; UNC2025 HCl; UNC 2025 hydrochloride; UNC-2025; UNC2025; UNC 2025

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO: ~100 mg/mL (194.9 mM)
Ethanol: ~60 mg/mL (116.9 mM)

Solubility in Formulation 1: ≥ 1 mg/mL (1.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 1 mg/mL (1.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: 100 mg/mL (194.89 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

---

 (Please use freshly prepared in vivo formulations for optimal results.)